- Statistically significant (p
Organogenesis Achieves Primary Endpoint in Randomized Controlled Trial of PuraPly®AM
On 6ix: 6ix.com/news/organogenesis-achieves-primary-endpoint-in-randomized-controlled-trial-of-puraplyram
Watch Organogenesis' latest callOrganogenesis Holdings (NASDAQ:ORGO) Q3 2026 Earnings Call · Replay · Nov 5Read the transcript of Organogenesis Holdings (NASDAQ:ORGO) Q3 2026 Earnings CallOrganogenesis Holdings Inc. on 6ix
Story so far
Earlier from Organogenesis
- Organogenesis Holdings Inc. Reports Fourth Quarter 2025 Financial Results, Posts Record Revenue
- Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 26, 2026
- Organogenesis Announces Initiation of Biologics License Application for ReNu®
- Organogenesis Announces Successful FDA Meeting and Plan to File BLA for ReNu® for Knee Osteoarthritis Pain
- Organogenesis Holdings Inc. Reports Third Quarter 2025 Financial Results, Posts Record Revenue and Raises 2025 Guidance
Later from Organogenesis
- Organogenesis Completes Rolling Submission of Biologics License Application for ReNu®
- Organogenesis Holdings Inc. Reports First Quarter 2026 Financial Results
- Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
- Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2026 Financial Results on August 6, 2026
- Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers
Follow Organogenesis into a list and get an email when it puts out news.
Follow Organogenesis